Answers are grounded in this paper and cite their sources.
Background Aprepitant (APR), including intravenous fosaprepitant, is widely used as an antiemetic for highly emetogenic chemotherapy. APR is a moderate inhibitor and inducer of CYP3A4 and may alter the pharmacokinetics of concomitant drugs over an extended period. Tacrolimus (TAC), a key immunosuppressant after allogeneic hematopoietic stem cell transplantation (allo-HSCT), is primarily metabolized by CYP3A4. The long-term effects of APR on TAC pharmacokinetics remain unclear. Methods This retrospective observational study included patients receiving TAC for at least 28 days after allo-HSCT between January 2006 and April 2017. Patients were classified into APR-treated (APR(+)) and non-APR-treated (APR(-)) groups. During the 28-day observation period, patients switched from intravenous to oral TAC were censored at conversion to exclude the influence of bioavailability. TAC was administered by continuous intravenous infusion at 0.03 mg/kg/day starting on day − 1 and adjusted by therapeutic drug monitoring to maintain a target level of 15 ng/mL. APR was initiated between day − 8 and day 1 and was administered for up to 5 days, orally or intravenously. The concentration/dose (C/D) ratio was used as a surrogate marker of TAC clearance. Results A total of 64 patients were assessed for eligibility. Of these, 16 who received voriconazole or itraconazole were excluded, leaving 48 patients (28 APR(+), 20 APR(-)). Baseline characteristics and use of moderate CYP3A4 inhibitors did not differ between groups. From days 0–4, TAC C/D ratios were similar. In APR(+), C/D ratio decreased from day 5 to day 10, remained low for approximately 3 weeks, and returned to day 5 levels by day 28. C/D values on day 10 ± 1 and day 20 ± 1 were significantly lower than APR(-) ( P < 0.01). TAC doses in APR(+) increased from around day 5, reaching approximately 30% above day 4 ± 1 during days 10–25, then decreased. Conclusions Co-administration of TAC and APR increases TAC clearance from day 5, likely due to CYP3A4 induction, and the effect persists for approximately 3 weeks. The prolonged induction may relate to concomitant fluconazole use or longer half-life of TAC. Gradual TAC dose escalation of approximately 30% from day 5, with frequent monitoring for 2–3 weeks, may help maintain adequate exposure while minimizing GVHD and adverse effects.
No takes yet. Share an insight, caveat, or question.
Hitachi-Yuzawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: